| http://www.w3.org/ns/prov#value | - Bottom line, we were very impressed with Novartis pharma head James Shannon on the analyst call - and also think the FDA action is probably not that unexpected given the issues that came up in the trial, especially the fact that they can not explain the skin lesions.
|
